Whether implicitly (as was the case in earlier years) Cytoskeletal Signaling or explicitly, they have had to balance the service they deliver to the individual patient in front of them with the needs of the larger population that they serve. The prioritisation of resources, whether of time, skills, services or money, in order to achieve the proper balance between populations and individuals, and between one

individual and another has been part of clinical practice for many decades. In the context of clinical genetics, this tension is often played out over the issue of reproductive choice. Informed consent is now a driving force, one accepted by public health practitioners and by the public health Androgen Receptor antagonist genomics movement. The reduction of the birth prevalence of inherited disorders will be welcomed by both practitioners of public health genomics and community GSK1120212 mw genetics (whether they regard it as the primary aim of a programme or merely a consequence), but both will insist that such reduction is legitimate if and only if this comes about as a consequence of real parental choice, without

coercion and without deception. Indeed, the experience that public health practitioners have in the balancing of values has enabled them to participate

in debates surrounding reproductive choice and other matters such as consent for genetic testing, genetic testing for minors and the establishment of biobanks. They participate in these discussions with as much knowledge and understanding as clinical geneticists, and holding, I would suggest, FER the same set of ethical values. The community genetics community embraces the need for evidence and for the responsible application of genomic knowledge for the benefit of their patients. This again is no different to the attitude of public health genomics and their requirement for evidence-based practice and policy. But rather than this being seen as a tension between evidence-based decision making and “individual decision making” (as it is termed in the paper), evidence-based medicine should be regarded as an aid, as a piece of data input, to help inform the judgments of clinicians and policy makers. The quote from Laberge in the paper, that “in public health genomics too, personal responsibility and empowerment are promoted as final objectives, making public health eventually the result of individual decisions of citizens” is a concept that I thoroughly agree with.